Three world-class experts will enable the company to enhance and expand its therapeutic practices

Wednesday, May 06, 2009 / Morrisville, NC — Clinipace, a growing digital clinical research organization, announced today that the company has added Drs. William McCulloch, Joseph DeVeaugh-Geiss, and Michael Hamrell as advisors to support the company’s team of clinical development professionals. The new advisors will enable Clinipace to enhance its existing clinical services while further deepening its therapeutic expertise.

  • William McCulloch, M.B. (“MD”), F.R.C.P., F.F.P.M. will advise the Oncology and Immunology team. Since 1984, Dr. McCulloch has been a prolific researcher in the pharmaceutical industry who has contributed to over a dozen IND and NDA submissions, 24 + scientific abstracts, published 14 peer-reviewed articles and contributed three chapters to Oncology-related treatment books. Prior to that he practiced medicine for seven years in the U.K.
  • Joseph DeVeaugh-Geiss, M.D. will advise the CNS, Psychiatry, and Internal Medicine team. Dr. DeVeaugh-Geiss has spent his 18+ year pharmaceutical career with CIBA-GEIGY, Glaxo, Glaxo Wellcome, and GlaxoSmithKline. During that time he contributed to and managed the successful submission and approval of a dozen NDAs and SNDAs. Since 2001, he has provided expert consultation to the pharmaceutical industry through his consulting company, BRAINSTORM CNS, LLC. He maintains academic appointments at the Duke University Medical Center, Duke Clinical Research Institute, University of North Carolina, SUNY Health Science Center and the American University of the Caribbean.
  • Michael R. Hamrell, Ph.D., RAC will advise the Clinipace Regulatory team. Dr. Hamrell has over 25 years of experience in regulatory affairs, clinical research and product development in academia, the FDA, NIH and in industry. He maintains academic appointments at the University of Southern California, the Massachusetts College of Pharmacy & Health Sciences, the University of North Carolina Wilmington, George Washington University, School of Medicine, and Touro University International. He has served on the Editorial Board of several research publications, is the Editor-in-Chief of the Drug Information Journal and has received numerous awards for his research, teaching and professional work.

“Partnering with these world-class experts enables us to continue our ongoing efforts to provide the best possible clinical research experience and services to sponsors and their clinical investigators,” said Jeff Williams, Chief Executive Officer at Clinipace.

Williams explained, “Over the years, Clinipace and our team have conducted and provided oversight for dozens of clinical studies. While not specializing in any one therapeutic area, we have significant experience in managing trials and registries across North America with a focus on Cardiovascular, Central Nervous System, Psychiatry, Oncology, Gastrointestinal disorders, Dermatology, Biologics and Immunology. By operationalizing the trial protocols with our technology-driven model, sponsors are assured that our experienced clinical trial specialists in project management, clinical and site monitoring, data management, and biostatistics deliver the solution and budget to fit any trial or project.”

About Clinipace

Clinipace is an experienced digital clinical research organization (dCRO) providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% – 50% savings compared to similar service providers.